President Trump has responded by putting the order on hold until August 25, so that pharmaceutical companies can propose an alternative solution to the President’s. While the White House further emphasized its support for the meeting on Monday, pharmaceutical companies seemed less enthused and have questioned the usefulness of the meeting.
In particular, drug lobbying companies PhRMA and BIO were hesitant to send representatives from their parent companies to the meeting.
A PhRMA spokesperson characterized the planned meeting as a waste of precious time in the midst of a pandemic, “The president’s plan to import policies from socialized health care systems abroad is disrupting our work [on Covid-19 therapies] and diverting our focus away from those life-saving efforts.”
As of today, the meeting has yet to be rescheduled, nor has an alternative solution been proposed to the executive order.
————————————————–
Have a story you want USA Herald to cover? Submit a tip here and if we think it’s newsworthy, we’ll follow up on it.
